Article
Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.
HIV medicine - 1 Jul 2004
Clevenbergh P, Boulmé R, Kirstetter M, Dellamonica P
Abstract excerpt
BACKGROUND: Amprenavir (APV) has been shown to be effective in naive or treatment-experienced HIV-1 infected patients. However, the safety and efficacy of the APV 600 mg/ritonavir (RTV) 100 mg twice a day (bid) combination, the usually recommended dosage for boosted APV, have been less well studied. We assessed the predictive factors associated with virological success of APV/RTV-based regimens. METHODS: Patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.